午夜福利利国产精品无码,午夜国产精品无码视频,精品午夜福利1000在线观看

<u id="dcio2"></u>
<strike id="dcio2"><video id="dcio2"></video></strike>
    <th id="dcio2"></th>

    <code id="dcio2"><nobr id="dcio2"><track id="dcio2"></track></nobr></code>

    1. <strike id="dcio2"><video id="dcio2"></video></strike>
      1. <object id="dcio2"></object>
         
        Home    Contact us    中文
        SZ&W >  Industry >  Biopharma & IVD
         
                 
        Nuclear Power
        Solar & Renewable
        Offshore & Marine
        Biopharma & IVD
        Oil & Gas
        Unconventional Gas
        Telecom & Media
        Transport & Logistic
        Finance & Investment
        Life Science
        Real Estate
        Retail & Entertainment
        Aerospace & Defense
        Power & Utilities
        Hospitality
        FinTrends
        Insurance
        Autonomous Vehicle
        New Energy Vehicle
        Automotive Lightweight
         
        Biopharma & IVD
         

        The global in vitro diagnostics market is forecast to grow from $53.3 billion in 2013 to $69.3 billion by the year 2018, according to EAC, predicted 4.9% annual growth assuming constant currency rates.

        By region, North America is the largest IVD market at $23.4 billion in 2013, followed by Europe/Middle East/Africa at $18.8 billion, Asia-Pacific at $5.9 billion, Japan at $3.9 billion and Latin America at $2.5 billion. But Asia-Pacific is the fastest growing region with continued double digit growth rates.

        By segment, 5 largest segments, in rank order, are Immunoassays, Whole Blood Glucose, Central Lab Clinical Chemistry, POC/POL and Clinical Molecular. However, the fastest growing segments in the past year were Clinical Molecular (7.9%), POC/POL testing (7.0%), Hematology (6.3%), Anatomic Pathology (6.2%) and Immunoassay (5.9%).

        By application, the IVD market can be divided into infectious disease, diabetes, cancer, cardiology, autoimmune diseases, nephrology, drug testing, and HIV/AIDS. Of these, infectious diseases, followed by HIV/AIDS testing are top two generators of revenue in the market currently and are expected to maintain their positions.

        By end user location, the vast majority of IVD testing (74%) is still performed in central laboratories, defined as hospital labs, private reference labs, and blood bank labs. An increasing proportion is being performed at point-of-care locations in hospitals as well as physician offices and other decentralized sites such as retail and community clinics (11%). Finally, consumer testing – either physician directed or Over-the-Counter (OTC) – represents 15% of the IVD market.

        Experts from Frost & Sullivan have given following key drivers and restraints for global IVD market in recent years:

        For IVD industry trends in the following years, we could expect IVD market will booming in Asia Pacific region and emerging markets. Infectious diseases and HIV/AIDS testing are attracting more priority. And molecular diagnostics and POCT segment will have faster growing rates. Diagnostic testing will continue to move towards decentralization.

        IVD Industry is a very huge attractive growing pie for all stakeholders, especially in emerging markets. SZ&W Group will commit to create commercial opportunities to our members to booming IVD business in emerging markets.

         
         
              Brand Events
         
















         
        Follow us  
        Twitter
        Facebook
        Linked in
        E-mail us
         
        © CopyRight by SZ&W|GROUP 2001-2021滬ICP備2021019987號-1
        午夜福利利国产精品无码,午夜国产精品无码视频,精品午夜福利1000在线观看